Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, AA patients and healthy controls showed no significant difference in carotid intima-media thickness, but AA patients had higher diastolic blood pressure and fasting blood glucose levels, indicating potential cardiovascular risks.

This study confirmed that the Alopecia Areata-Investigator Global Assessment and other clinical outcome assessments are valid and relevant measures of treatment success for alopecia areata patients in Japan, aligning with previous North American findings.

In this study, researchers examined trichoscopic features in a cohort of Black patients with alopecia areata, identifying both common and novel characteristics, but found no statistical link between these features and the severity of alopecia.

This study developed a questionnaire based on Andersen’s behavioral model to explore psychological well-being and mental health help-seeking behaviors among alopecia areata patients from underserved communities, aiming to better understand factors influencing their mental healthcare utilization.

In this case report, a patient with diffuse alopecia areata experienced complete hair regrowth after treatment with oral abrocitinib, with no adverse effects observed.

This study identified a new genetic locus, ahl4, on distal Chromosome 10 that contributes to the early-onset, severe hearing loss in A/J mice compared to B6 mice.

This study found that young patients with severe AA are more prone to nail abnormalities such as pitting and leukonychia, with koilonychia and red spots lunula in more severe cases.

In this case report, complete hair regrowth was observed in a patient with autoimmune-related alopecia areata after treatment with a Janus kinase inhibitor, suggesting its potential effectiveness for both genetic and sporadic forms of the condition.

This study found that patients with alopecia areata had significantly lower serum levels of autophagy-related protein 5, indicating a potential role of dysfunctional autophagy in the disease's pathogenesis.

This review discusses the National Alopecia Areata Foundation's efforts to evaluate and advance alopecia areata research, focusing on immunology and drug development, and reports no new clinical results.

Alopecia areata is linked to immune-related genes, suggesting JAK inhibitors as a potential treatment.

This study found that alopecia areata patients had a slightly decreased overall cancer risk, with significantly lower risks for some cancers but higher risks for lymphoma, breast, kidney, and urinary bladder cancers.

This study found that full-length Agouti protein modulates melanocortin receptor signaling through a dual mechanism involving competitive antagonism and receptor down-regulation, whereas the carboxyl-terminal fragment acts solely as a competitive antagonist.

UVA exposure worsens hair loss by activating a specific cell pathway.

This study suggests a new subtype of alopecia, termed 'acute diffuse and total alopecia of the female scalp' (ADTAFS), characterized by acute and total hair loss in women with a favorable recovery profile.

This article reviews the characteristics of alopecia areata, highlights the psychological factors involved, and discusses South American contributions to understanding the disease, but reports no new clinical results.

This study found that A-FABP serum levels were significantly higher in male patients with androgenetic alopecia compared to controls, and the authors concluded that A-FABP could serve as a biomarker for early detection of this condition.

This study examined FAERS data and found an increasing trend in alopecia areata cases, with monoclonal antibodies most frequently linked to the condition.

Topical minoxidil and anthralin work for patchy alopecia areata but not for alopecia totalis/universalis.

This study found that patients with severe alopecia areata demonstrated reduced corneal sensitivity and increased corneal staining, and exhibited altered topographic and biomechanical eye parameters compared to controls, suggesting a possible increased risk of keratoconus and the necessity for regular ophthalmological exams.

This study reports a notable case of a patient with psoriatic arthritis and alopecia universalis who experienced significant improvement in both conditions after treatment with the JAK1 selective inhibitor upadacitinib, suggesting its potential efficacy for alopecia universalis, especially in cases involving inflammatory arthritis.

This study tested a novel cryo-carboxy dispensing device for treating androgenetic alopecia in six volunteers and found an unexpectedly rapid and positive response, with significant hair regrowth observed by day 90, prompting early conclusion of the trial.

This review discusses the approval of deuruxolitinib, an oral JAK inhibitor, by the FDA in July 2024 for treating severe alopecia areata in adults, highlighting its role as the third approved oral treatment option alongside baricitinib and ritlecitinib.

This study suggests that combining microneedling with ALA-photodynamic therapy may be a promising treatment option for moderate to severe alopecia areata, achieving significant hair regrowth in some patients.

This article discusses the etiology, clinical features, diagnosis, histopathology, and treatment of alopecia areata but reports no new clinical findings; it emphasizes the palliative nature of current treatments.

This study analyzed survey responses from 800 alopecia areata patients and found a possible genetic association with increased insulin-dependent diabetes mellitus in relatives but not in the patients themselves.

In this study conducted at Al-Azhar University Hospital, 60% of patients with localized alopecia areata responded to treatment with autologous platelet-rich plasma, with 89% of responders showing substantial improvement, suggesting PRP as an effective treatment option for this condition.

In this retrospective study, researchers found a statistically significant increase in the risk of alopecia areata among atopic dermatitis patients using dupilumab compared to controls, suggesting the need for careful monitoring and further research on the drug's impact on alopecia areata.

This study evaluated 308 nm excimer light therapy for alopecia areata but the abstract does not provide specific clinical results or conclusions.

The authors concluded that alopecia areata incognita, mainly affecting young females, generally has a more favorable prognosis than other types of alopecia areata.